ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM: Abstract Number: 2202

Epidemiologic Evaluation of Postpartum Mental Health for Women Living with Systemic Lupus Erythematosus: A Population-Based Cohort Study Among Medicaid Enrollees

(2195–2226) Reproductive Issues in Rheumatic Disorders Posters

10:30AM-12:30PM: Abstract Number: 1901

Epidemiology of Adult-Onset Still’s Disease in South Korea: A Nationwide Study Using Health Insurance Claims Data

(1877–1913) Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 1818

Epigenetic Profiling of Childhood-onset Lupus Reveals Distinct Epigenetic Clusters and Suggests Epigenetic Drivers of Disease Activity

(1809–1829) Pediatric Rheumatology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 2555

Ergonomic Modifications: Findings From the Making it WorkTM Systemic Sclerosis Program

(2547–2566) ARP Posters I

10:30AM-12:30PM: Abstract Number: 2085

Estimating the Association between Effusion-synovitis and Knee Pain in a Subset of Participants with Radiographic Knee Osteoarthritis: Data from the Osteoarthritis Initiative (OAI)

(2079–2105) Osteoarthritis – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1932

Evaluating a Potential Cause of Excess Lung Cancer Mortality in RA: An Analysis of Chest CT Imaging Frequency in RA

(1914–1935) Health Services Research Poster III

10:30AM-12:30PM: Abstract Number: 2041

Evaluating Biologic Effectiveness in Co-Occurring Dermatologic and Rheumatic Disease: A Systematic Review

(2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 2158

Evaluating Nailfold Capillary Changes as Indicators of Disease Activity in Juvenile Dermatomyositis

(2124–2158) Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2003

Evaluating Patient Outcomes Pre and Post Pegloticase Initiation among Uncontrolled Gout Patients: Findings from MORE2 Registry and Medicare Fee-For-Service Claims Data

(1990–2014) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 2094

Evaluating the Accuracy of Knee Acoustic Emissions Classification of Varus Thrust

(2079–2105) Osteoarthritis – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1973

Evaluating the Impact of Clinical Pharmacist Integration on Patient Care Outcomes in a Private Rheumatology Clinic

(1972–1989) Measures & Measurement of Healthcare Quality Poster II

10:30AM-12:30PM: Abstract Number: 2415

Evaluating the Readability and Comprehension of Patient Education Materials for Systemic Lupus Erythematosus (SLE) Available Online

(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1987

Evaluating User Engagement and Real-World Impact of a PMR-Specific Digital Symptom Assessment Tool: A 12-Month Analysis of PainSpot™

(1972–1989) Measures & Measurement of Healthcare Quality Poster II

10:30AM-12:30PM: Abstract Number: 2083

Evaluation of a Parent-Trial as a Run-In Period: Efficacy and Safety of Repeat Injections of Lorecivivint over Three Years

(2079–2105) Osteoarthritis – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 2249

Evaluation of a Screening Tool for Identifying Risk of Subclinical Interstitial Lung Disease in Rheumatoid Arthritis Patients Treated with Targeted Therapies

(2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].